Abstract: The present disclosure describes a multi-initialization ensemble-based defense strategy against an adversarial attack. In one embodiment, an exemplary method includes training a plurality of conventional neural networks (CNNs) with a training set of images, wherein the images include original images and images modified by an adversarial attack; after training of the plurality of conventional neural networks, providing an input image to the plurality of conventional neural networks, wherein the input image has been modified by an adversarial attack; receiving a probability output for the input image from each of the plurality of conventional neural networks; producing an ensemble probability output for the input image by combining the probability outputs from each of the plurality of conventional neural networks; and labeling the input image as belonging to one of the one or more categories based on the ensemble probability output.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: Pre-treatment clinical data and radiomic features extracted from computed tomography (CT) scans were used to develop a parsimonious model to predict survival outcomes among NSCLC patients treated with immunotherapy. The biological underpinnings of the radiomics features were assessed utilizing geneexpression information from a well-annotated radiogenomics NSCLC dataset and were further assessed for survival in four independent NSCLC cohorts. Therefore, disclosed herein is a method for predicting efficacy of immunotherapy in a subject with lung cancer using the disclosed radiomic features.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: A positive air pressure system resists debris accumulation on an active surface and comprises a frustum-shaped shroud with a baffle plate therein dividing the shroud into baffles, including a positive pressure chamber and a passive back pressure chamber interconnected through an orifice in the baffle plate. An inlet opening is formed in the shroud and in fluid communication with the proximal baffle and a positive pressure air source and to receive air through the inlet opening from the positive pressure air source and create a high-pressure region, greater than a pressure region in the passive back pressure chamber, and in front of the active surface and to expel air out of the positive pressure chamber and into the passive back pressure chamber through the orifice in the baffle plate.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expressing tumors which confirmed by Western blot and IHC analysis supported. Using Hela tumor bearing models with IFN-? treatment confirmed that [18F]IDO49 accumulation in the IFN-? treatment tumor mouse. These results can have implications that [18F]IDO49 has substantial potential as an imaging agent that targets IDO in tumors.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: A positive air pressure system resists debris accumulation on an active surface and comprises a frustum-shaped shroud with a baffle plate therein dividing the shroud into baffles, including a positive pressure chamber and a passive back pressure chamber interconnected through an orifice in the baffle plate. An inlet opening is formed in the shroud and in fluid communication with the proximal baffle and a positive pressure air source and to receive air through the inlet opening from the positive pressure air source and create a high-pressure region, greater than a pressure region in the passive back pressure chamber, and in front of the active surface and to expel air out of the positive pressure chamber and into the passive back pressure chamber through the orifice in the baffle plate.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.

Abstract: The present invention generally relates to methods of preselecting patients for treatment with an anti-VEGF therapy, anti-HIF-1 therapy or anti-thioredoxin therapy. Aspects of the invention combine methods of dynamic contrast enhanced-MRI and diffusion weighted-MRI for the detection of tumor histology. The methodology disclosed herein detects tissue blood volume, tumor vascularity, and abnormal capillary permeability, thereby determining tumor vascularity to determine whether a patient should be administered such therapy.

Abstract: The present invention is directed to methods for treating acne. The methods include exposing the subject afflicted with acne to ultraviolet light having a wavelength between about 320 to about 350 nm, such that the acne is treated, e.g., inhibited, diminished, eradicated or prevented. In a preferred embodiment, the wavelength is 335 nm and is emitted by either a nitrogen laser or a third harmonic of a NdYAG laser. Treatments can be administered over a several week period, where the subject is exposed to sequential doses of ultraviolet light to obtain beneficial effects, e.g., a reduction or elimination of the acne, e.g., an eradication or diminishment of the bacteria responsible for acne, e.g., Propionibacterium acnes.

Abstract: The present invention refers to the use of a selection of imidazole compounds in a method of obtaining extracellular or intracellular pH images in biological systems, by magnetic resonance, consisting of administering the imidazole compound to said biological system and acquiring a pH image through magnetic resonance measurements, and said method selected from the group consisting of proton magnetic resonance chemical shift imaging (1H CSI), proton magnetic resonance spectroscopic imaging (1H MRSI), fluorine magnetic resonance chemical shift imaging (19F CSI), fluorine magnetic resonance spectroscopic imaging (19F MRSI), and combinations thereof.

Abstract: The method of the present invention is directed at detecting non-invasively and in vivo the rate of proliferation of epithelial cells in a human patient. The method is based on determining the optical spectra, preferably the fluorescence excitation spectra, from affected and non-affected areas of epithelial cells, and then comparing the two spectra from these regions. In particular, applicants have discovered that when human or animal skin is irradiated with light centered near 295 nm, fluorescence having a distinct maximum near 360 nm is induced.